Soleno Therapeutics, Inc. (SLNO)
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- GlobeNewswire
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL. The presentation will be available on-demand beginning at 7 AM Eastern
- Zacks
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
The FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic kidney disease. The company plans to begin a phase I study in second-quarter 2022. Stock up.
